

Modern tools and new evidence in staging of urothelial carcinomas

Poster Session 29

Sunday, 26 March
12:15 - 13:45

Location: Room Madrid, North Hall (Level 1)

Chairs: M.J. Ribal, Barcelona (ES)
D.J. Rosario, Sheffield (GB)
T. Seisen, Paris (FR)

Aims and objectives of this session

The proper diagnostic pathway, including demands for pathology and imaging, is an ongoing debate in bladder cancers.

Non-muscle invasive papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). New molecular biology techniques and clinical experience can pinpoint the highly malignant potential of selected CIS and T1 lesions. In muscle invasive bladder cancer both computed tomography (CT) and magnetic resonance imaging (MRI) may be used to detect T3b or higher disease. However, assessment of lymph node metastases with CT or MRI based on size and morphology has its limitations. This session aims to highlight new insights in the work-up of these tumors.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

380

Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: A prospective multicenter validation study

By: Dyrskjöt L.², Reinert T.², Algaba F.³, Christensen E.², Nieboer D.⁴, Hermann G.⁵, Morgensen K.⁵, Marquez M.⁶, Segersten U.⁷, Hoyer S.⁸, Ulhøj B.⁸, Hartmann A.⁹, Stöhr R.⁹, Wach S.¹⁰, Nawroth R.¹¹, Beukers W.²⁰, Schwamborn K.¹², Tulic C.¹³, Simic T.¹⁴, Junker K.¹⁵, Harving N.¹⁶, Petersen A.C.¹⁷, Jensen J.B.¹⁸, Keck B.¹⁰, Horstmann M.¹, Maurer T.¹⁹, Steyerberg E.⁴, Zwarthoff E.²⁰, Real F.⁶, Malats N.²¹, Malmström P-U.⁷, Ørntoft T.F.²

Institutes:¹Friedrich Schiller University of Jena, Dept. of Urology, Jena, Germany, ²Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ³University Autònoma de Barcelona, Section of Pathology, Fundació Puigvert, Barcelona, Spain, ⁴Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ⁵Frederiksberg Hospital, Dept. of Urology, Frederiksberg, Denmark, ⁶Spanish National Cancer Research Centre, CNIO, Madrid, Spain, ⁷Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁸University of Aarhus, Dept. of Pathology, Aarhus, Denmark, ⁹University Hospital of Erlangen, Dept. of Pathology, Erlangen-Nürnberg, Germany, ¹⁰University Hospital Erlangen, Dept. of Urology, Erlangen, Germany, ¹¹Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ¹²Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Pathology, Munich, Germany, ¹³Faculty of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, ¹⁴Faculty of Medicine, University of Belgrade, Institute of Medical and Clinical Biochemistry, Belgrade, Serbia, ¹⁵Saarland University, Dept. of Urology, Homburg, Germany, ¹⁶Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ¹⁷Aalborg University Hospital, Dept. of Pathology, Aalborg, Denmark, ¹⁸Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ¹⁹Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ²⁰Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²¹Universitat Pompeu Fabra, Dept. of Experimental Science, Barcelona, Spain

381

11C-acetate PET-MRI in bladder cancer staging

By: Salminen A.¹, Jambor I.², Merisaari H.³, Ettala O.¹, Virtanen J.², Koskinen I.⁴, Veskimäe E.⁵, Sairanen J.⁴, Minn H.⁶, Kempainen J.⁷, Boström P.¹

Institutes:¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital,

Dept. of Diagnostic Radiology, Turku, Finland, ³University of Turku, Dept. of Information Technology, Turku, Finland, ⁴Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁵Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁶Turku University Hospital, Dept. of Clinical Oncology, Turku, Finland, ⁷Turku University Hospital, Dept. of Clinical Physiology, Nuclear Medicine and PET Imaging, Turku, Finland

- 382 **Metric sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer**
 By: Fransen Van De Putte E.¹, Van Der Kwast T.², Bertz S.³, Denzinger S.⁴, Manach Q.⁵, Compérat E.⁶, Boormans J.⁷, Jewett M.⁸, Stoehr R.³, Zlotta A.⁹, Hendricksen K.¹, Rouprêt M.⁵, Otto W.⁴, Burger M.⁴, Hartmann A.³, Van Rhijn B.¹
Institutes:¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²University of Toronto, Princess Margaret Cancer Center, Dept. of Pathology, Toronto, Canada, ³University of Erlangen, Dept. of Pathology, Erlangen, Germany, ⁴University of Regensburg, Caritas Krankenhaus St. Joseph, Dept. of Urology, Regensburg, Germany, ⁵Hôpital Universitaire Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁶Hôpital Universitaire Pitié-Salpêtrière, Dept. of Pathology, Paris, France, ⁷Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁸University of Toronto, Princess Margaret Cancer Center, Dept. of Surgery (Urology), Toronto, Canada, ⁹University of Toronto, Mount Sinai Hospital, Dept. of Surgery (Urology), Toronto, Canada
- 383 **A panel of micro-RNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder**
 By: Inamoto T.¹, Takahara K.², Ibuki N.², Takai T.², Uchimoto T.², Saito K.², Tanda N.², Yoshikawa Y.², Minami K.², Hirano H.², Nomi H.², Azuma H.²
Institutes:¹Osaka Medical College, Osaka, Japan, ²Osaka Medical College, Dept. of Urology, Osaka, Japan
- 384 **Using the EORTC risk tables & the CUETO scoring model for predicting recurrence and progression in non-muscle invasive bladder cancer: A local single centre experience**
 By: Lee S.L., Lim S.K., Ng K.K., Ng F.C.
Institutes:Changi General Hospital, Dept. of Urology, Singapore, Singapore
- 385 **Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma**
 By: Todenhöfer T.¹, Vandekerckhove G.², Struss W.², Annala M.², Beja K.², Eigl B.², Mischinger J.¹, Stenzl A.¹, Black P.², Wyatt A.²
Institutes:¹Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ²University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada
- 386 **Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and morphological imaging in recurrent urothelial carcinomas: A retrospective, multi-center study**
 By: Zattoni F.¹, Ficarra V.², Briganti A.³, Colicchia M.⁴, Fanti S.⁵, Karnes R.J.⁴, Incerti E.⁶, Lowe V.⁷, Moschini M.³, Panareo S.⁸, Picchio M.⁶, Rambaldi I.⁹, Schiavina R.¹⁰, Zattoni F.¹², Evangelista L.¹¹
Institutes:¹University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ²University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, ³Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁵Sant'Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, ⁶IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ⁷Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, ⁸University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, ⁹University Hospital of Ferrara, Nuclear Medicine Unit, Diagnostic Imaging E Laboratory Medicine Department, Ferrara, Italy, ¹⁰Sant'Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ¹¹Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy, ¹²University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy
- 387 **Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers**

By: Hayashi T.¹, Sentani K.², Kakumoto S.¹, Oo H.Z.³, Sakamoto N.², Mutaguchi K.⁴, Kobatake K.¹, Goto K.¹, Inoue S.¹, Teishima J.¹, Yasui W.², Black P.C.³, Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ³Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ⁴Nakatsu Daiichi Hospital, Dept. of Urology, Nakatsu, Japan

388

Validation of preoperative thrombocytosis as adverse prognostic factor in advanced bladder cancer (BCA) after radical cystectomy (RC)

By: Foerster B.¹, Moschini M.¹, Abufaraj M.¹, Soria F.¹, Lotan Y.², Karakiewicz P.³, Briganti A.⁴, Babjuk M.⁵, Rink M.⁶, Kluth L.⁶, John H.⁷, Shariat S.¹

Institutes:¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ³University of Montreal, Dept. of Urology, Montreal, Canada, ⁴Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁵Faculty Hospital Motol, Second Faculty of Medicine, Charles University In Praha, Dept. of Urology, Prague, Czech Republic, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

389

Preoperative hemoglobin to platelet ratio as a predictor of survival after radical cystectomy due to bladder cancer, synergic effect of anemia and thrombocytosis

By: La Croce G.¹, Moschini M.¹, Dell'Oglio P.¹, Nini A.¹, Bandini M.¹, Capogrosso P.¹, Ventimiglia E.¹, Sanchez-Salas R.², Salonia A.¹, Briganti A.¹, Montorsi F.¹, Gallina A.¹, Colombo R.¹

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²L'Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

390

Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort

By: Seiler R.¹, Oo H.Z.², Todenhöfer T.², Fazli L.², Daugaard M.², Black P.²

Institutes:¹Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, ²University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada

391

Potential utility of apparent diffusion coefficient (ADC) value as a biomarker to predict the difference between T1G3 non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC)

By: Masaaki F.¹, Sakamoto S.², Sekita N.¹, Sato H.¹, Kono H.¹, Nishikawa R.¹, Takeuchi N.², Suzuki H.³, Mikami K.⁴, Ichikawa T.²

Institutes:¹Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Narashino, Japan, ²Chiba University, Dept. of Urology, Chiba, Japan, ³Toho University Medical Center, Sakura Hospital, Dept. of Urology, Sakura, Japan, ⁴Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Sakura, Japan

392

The effects of 18F-FDG PET/CT on the management and prognosis of patients with bladder cancer (BCa) and upper urinary tract urothelial carcinoma (UTUC)

By: Zattoni F.¹, Briganti A.², Colicchia M.³, Castellucci P.⁴, Ficarra V.⁵, Karnes R.J.³, Fallanca F.⁶, Lowe V.⁷, Massari F.⁸, Gallina A.², Bartolomei M.⁹, Picchio M.⁶, Ippolito C.¹⁰, Schiavina R.¹¹, Zattoni F.¹, Evangelista L.¹²

Institutes:¹University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy, ²URI, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Sant'Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, ⁵University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, ⁶IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Nuclear Medicine, Milan, Italy, ⁷Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, ⁸S. Orsola-Malpighi Hospital, Dept. of Medical Oncology, Bologna, Italy, ⁹University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, ¹⁰University- Hospital of Ferrara, Dept. of Surgery, Ferrara, Italy, ¹¹Sant'Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ¹²Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy

13:30 - 13:37

Summary

D.J. Rosario, Sheffield (GB)